Autres langues Ultragenyx Pharmaceutical Inc.

Actions

RARE

US90400D1081

Temps réel estimé Cboe BZX Autres places de cotation 16:30:06 15/05/2024			Varia. 5j.	Varia. 1 janv.
41,48 ^USD	+1,26 %		+0,12 %	-12,99 %

14/05	Korro Bio réduit sa perte nette au 1er trimestre ; Kemi Olugemo est nommé directeur médical	MT
14/05	Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	14/05
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference	07/05
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference	07/05
Ultragenyx: Q1 Earnings Snapshot	02/05
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $108.8M	02/05
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update	02/05
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	02/05
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta	01/05
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease	30/04
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)	30/04
Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta (OI)	30/04
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update	25/04
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - April 19, 2024	22/04
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	19/04
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	15/04
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology 2024 Annual Meeting	15/04
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	15/04
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	15/04
Sector Update: Health Care Stocks Advance Premarket Monday	15/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ultragenyx Pharmaceutical Inc.

Actions

RARE

US90400D1081

Autres langues

Filtres